Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


E-Prescribing Standards Should Limit Commercial Information, Sen. Grassley Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Electronic Rx systems should prevent drug marketing information from influencing physicians’ prescription choices, the Senate Finance Committee chair says in letter to National Committee on Vital & Health Statistics. Pfizer, J&J agree that process should be “neutral and unbiased.”

You may also be interested in...

E-Prescriber Access To Non-Preferred Drug Listings Is Industry Concern

Physicians should not have to scroll or click through new windows to see non-preferred and off-formulary drugs, Pfizer, J&J tell the standards subcommittee of the National Committee on Vital & Health Statistics.

“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says

Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts